We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




ACTH Stimulation Test Results Reassessed

By LabMedica International staff writers
Posted on 12 May 2018
Print article
Image: A diagram of types of adrenal insufficiency; CRH: corticotropin-releasing hormone, ACTH: adrenocorticotropic hormone (Photo courtesy of US National Institute of Health).
Image: A diagram of types of adrenal insufficiency; CRH: corticotropin-releasing hormone, ACTH: adrenocorticotropic hormone (Photo courtesy of US National Institute of Health).
Cosyntropin (adrenocorticotropic hormone or ACTH) stimulation testing is considered the gold standard for investigating primary adrenal insufficiency (AI) and may be an effective alternative to insulin tolerance testing in the workup of secondary AI.

The time of day that ACTH stimulation testing takes place does not affect the percentages of failed, borderline, or passed results in the evaluation of AI. However, testing sites also have different practices about the time of day (morning versus afternoon) that ACTH testing takes place.

Scientists at Dalhousie University (Saint John, NB, Canada) conducted a retrospective study of all ACTH testing performed during a 10-year period to assess whether both 30- and 60-minute results are necessary and whether the timing of testing affects outcomes. In all, there were 431 ACTH stimulation tests; the team excluded 92 due to medications the patients were taking or because the patients had already been diagnosed with primary AI.

The cutoff for ACTH testing was 18 mcg/dL (500 nmol/L) with a test “fail” if both 30- and 60-minute results were below this level, a “borderline pass” if either a 30- or 60-minute value was below the cutoff, and a pass if results at both time frames were above the cutoff. The investigators considered the time of day in three blocks of time: early morning (between 08.00 and 10.00); late morning (between 10:01. and 12:00); and afternoon (after 12:00).

The scientists found that there were no differences at the different time intervals in mean cortisol levels at 30 (574.5, 559, 534 nmol/L, respectively) and 60 minutes (642, 623, 619 nmol/L, respectively) between groups. When comparing 30- versus. 60-min values using a cut-off of ≥500 nmol/L, 45 patients (13.4%) failed to reach the cut-off at 30 minutes, but met the cut-off at 60 minutes. Conversely, only two patients (0.6%) who met the cut-off at 30 minutes failed to reach it at 60 minutes.

The authors concluded that outcomes from ACTH testing are not affected by time of day. Furthermore, using a 30-minutes cortisol level in isolation results in more than one in seven patients having a false positive diagnosis of AI; a 60-minutes value of ≥500 nmol/L alone may be sufficient to diagnose AI in more than 99% of cases. The study was published in the April 2018 issue of the journal Clinical Biochemistry.

Related Links:
Dalhousie University

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
New
Biological Indicator Vials
BI-O.K.

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.